Decision-making on listing new medicines for public funding in New Zealand: the case of ‘new’ type 2 diabetes medications
Open Access
- 13 April 2022
- journal article
- research article
- Published by CSIRO Publishing in Journal of Primary Health Care
- Vol. 14 (1) , 13-20
Abstract
Introduction: New medicines for the management of type 2 diabetes became available internationally in 2005, yet only in 2018 did the first of these become available in New Zealand. Access to these new medicines in New Zealand is largely dependent on decisions made by the Pharmaceutical Management Agency (PHARMAC). Aim: This study sought to describe the decision-making processes to better understand access to new medicines in New Zealand. Methods: We conducted an analysis of publicly accessible information on therapeutic committee deliberations, prices of medicines and registration and formulary listing dates. Results: Prices for the new diabetes medicines in New Zealand are lower than comparator countries, but access to them takes longer. Discussion: Given that knowledge on efficacy, safety and quality is widely available to support decision-making on new medicines, differences in access to them between nations appears to depend on the fourth hurdle of cost. However, we suggest that a rush to market is the norm, that activities of the pharmaceutical industry and regulatory agencies are less transparent than desirable, and that greater focus on availability of safety data is required. Deliberations of PHARMAC therapeutic committees are robust yet protracted. Opportunities to expedite decision-making, as well as resolving inequities, may be worthy of examination.Keywords
This publication has 15 references indexed in Scilit:
- Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverageCanadian Medical Association Journal, 2017
- Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New ZealandSeminars in Oncology, 2016
- Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New ZealandAustralian Health Review, 2015
- Assessment of the therapeutic value of new medicines marketed in AustraliaJournal of Pharmaceutical Policy and Practice, 2013
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Crossing the fourth hurdleBritish Journal of Clinical Pharmacology, 2012
- How New Zealand has contained expenditure on drugsBMJ, 2010
- Superior efficacy of new medicines?European Journal of Clinical Pharmacology, 2010
- Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitusCochrane Database of Systematic Reviews, 2008
- RISK VERSUS RISK: Decision-making Dilemmas of Drug Regulation in the United States and GermanyScience as Culture, 2000